US 11,857,543 B2
Compositions and methods for treating anemia
Robert Shalwitz, Bexley, OH (US); Charlotte Hartman, Carmel, IN (US); Akshay Buch, West Chester, OH (US); Isaiah Shalwitz, Columbus, OH (US); John Janusz, West Chester, OH (US); and Joseph Gardner, Cincinnati, OH (US)
Assigned to Akebia Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 14/897,849
Filed by Akebia Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Jun. 4, 2014, PCT No. PCT/US2014/040889
§ 371(c)(1), (2) Date Dec. 11, 2015,
PCT Pub. No. WO2014/200773, PCT Pub. Date Dec. 18, 2014.
Claims priority of provisional application 61/912,185, filed on Dec. 5, 2013.
Claims priority of provisional application 61/898,885, filed on Nov. 1, 2013.
Claims priority of provisional application 61/898,890, filed on Nov. 1, 2013.
Claims priority of provisional application 61/889,478, filed on Oct. 10, 2013.
Claims priority of provisional application 61/834,808, filed on Jun. 13, 2013.
Prior Publication US 2016/0143891 A1, May 26, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/44 (2006.01); A61K 31/4412 (2006.01); A61K 9/00 (2006.01); A61K 33/26 (2006.01); A61K 38/18 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4412 (2013.01); A61K 33/26 (2013.01); A61K 38/1816 (2013.01)] 30 Claims
 
1. A method for treating anemia secondary to or associated with chronic kidney disease, comprising orally administering to a patient having said anemia an effective amount of a compound which is {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid having the structure,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein a daily dose comprises 150±30 mg, 300±30 mg, 450±30 mg, 600±30 mg, or 750±30 mg of the compound.